Evolus Announces FDA Approval Of Evolysse Form And Evolysse Smooth Injectable Hyaluronic Acid Gels; First Major Technological Breakthrough In Hyaluronic Acid Dermal Fillers In A Decade; U.S. Launch Planned In Q2 2025

Evolus -6.50%

Evolus

EOLS

4.03

-6.50%

First Major Technological Breakthrough in Hyaluronic Acid Dermal Fillers in a Decade; U.S. Launch Planned in Q2 2025

Launch Establishes Evolus as a Multi-Product Performance Beauty Company and Expands Addressable Market by 78%

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection. These approvals mark Evolus' entry into the U.S. HA dermal filler market and solidifies the company's position as a multi-product innovator in aesthetics, expanding Evolus' total addressable market by 78% to approximately $6 billion1.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.